These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 36507829)

  • 1. Effects of Robuvit® on the progression of non-alcoholic fatty liver disease.
    Belcaro G; Cox DM; Cesarone MR; Gizzi G; Pellegrini L; Scipione C; Scipione V; Dugall M; Hu S; Corsi M; Feragalli B; Cotellese R
    Minerva Gastroenterol (Torino); 2022 Dec; 68(4):434-441. PubMed ID: 36507829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hangover and fatigue: effects of Robuvit® supplementation. A pilot registry study.
    Hu S; Belcaro G; Cesarone MR; Scipione C; Scipione V; Hosoi M; Cornelli U; Pellegrini L; Dugall M; Feragalli B; Cotellese R
    Minerva Cardioangiol; 2020 Jun; 68(3):203-208. PubMed ID: 32586071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supplementary management of functional, temporary alcoholic hepatic damage with Robuvit® (French oak wood extract).
    Pellegrini L; Belcaro G; Dugall M; Corsi M; Luzzi R; Hosoi M
    Minerva Gastroenterol Dietol; 2016 Sep; 62(3):245-52. PubMed ID: 27404261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supplementation with Robuvit® in subjects with burnout associated to high oxidative stress.
    Belcaro G; Hosoi M; Feragalli B; Luzzi R; Dugall M
    Minerva Med; 2018 Jun; 109(3):211-217. PubMed ID: 29164838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robuvit® reduces fatigue after chemotherapy for colon cancer. A pilot registry study.
    Belcaro G; Cox D; Cesarone MR; Scipione C; Scipione V; Dugall M; Hu S; Corsi M; Cornelli U; Feragalli B; Cotellese R; Selvaggi F
    Minerva Surg; 2023 Aug; 78(4):378-384. PubMed ID: 36995285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the concept of vigor and dys-vigor in men of 50-65 years: effects of Robuvit®.
    Ledda A; Hosoi M; Cesarone MR; Dugall M; Hu S; Belcaro G; Maione C; Cotellese R; Feragalli B; Scipione V; Scipione C
    Panminerva Med; 2020 Sep; 62(3):131-134. PubMed ID: 32716149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
    Amernia B; Moosavy SH; Banookh F; Zoghi G
    BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robuvit®: improvement of fatigue in medical convalescence.
    Ippolito E; Belcaro G; Luzzi R; Hosoi M; Dugall M; Rohdewald P; Feragalli B; Cotellese R; Peterzan P
    J Sports Med Phys Fitness; 2018 May; 58(5):678-683. PubMed ID: 29719945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robuvit® (French oak wood extract) in the management of functional, temporary hepatic damage. A registry, pilot study.
    Belcaro G; Gizzi G; Hu S; Dugall M; Pellegrini L; Cornelli U; Cesarone MR; Trignani M; Maione C
    Minerva Med; 2014 Feb; 105(1):41-50. PubMed ID: 24572451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved management of primary chronic fatigue syndrome with the supplement French oak wood extract (Robuvit®): a pilot, registry evaluation.
    Belcaro G; Cornelli U; Luzzi R; Cesarone MR; Dugall M; Feragalli B; Hu S; Pellegrini L; Ippolito E
    Panminerva Med; 2014 Mar; 56(1):63-72. PubMed ID: 24231834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supplementary management of functional, temporary alcoholic hepatic damage with Robuvit® (French oak wood extract).
    Pellegrini L; Belcaro G; Dugall M; Corsi M; Luzzi R; Hosoi M
    Minerva Gastroenterol Dietol; 2016 Mar; ():. PubMed ID: 26938040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of work-related stress, fatigue, loss of cognitive function, improved attention and recovery of stamina with Robuvit® in professionals with increased oxidative stress.
    Belcaro G; Cesarone MR; Saggino A; Dugall M; Hu S; Scipione C; Scipione V; Cornelli U; Hosoi M; Cotellese R; Cox D; Corsi M; Feragalli B
    Minerva Med; 2022 Jun; 113(3):518-525. PubMed ID: 34542952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robuvit® (Quercus robur extract) supplementation in subjects with chronic fatigue syndrome and increased oxidative stress. A pilot registry study.
    Belcaro G; Cornelli U; Luzzi R; Ledda A; Cacchio M; Saggino A; Cesarone MR; Dugall M; Feragalli B; Hu S; Pellegrini L; Ippolito E
    J Neurosurg Sci; 2015 Jun; 59(2):105-17. PubMed ID: 25394351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
    Türker F; Oral A; Şahin T; Türker BÇ; Koçak E; Ataoğlu HE; Ahbab S
    J Int Med Res; 2021 Nov; 49(11):3000605211056841. PubMed ID: 34763561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatigue due to mild heart failure: effects of Robuvit® in a concept, pilot registry study.
    Belcaro G; Cesarone MR; Scipione V; Scipione C; Dugall M; Hu S; Hosoi M; Cotellese R; Olivieri N; Feragalli B; Ledda A
    Minerva Cardioangiol; 2020 Jun; 68(3):216-223. PubMed ID: 32586072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supplementation with Robuvit® in post-traumatic stress disorders associated to high oxidative stress.
    Belcaro G; Luzzi R; Hosoi M; Dugall M; Cesarone MR
    Minerva Med; 2018 Oct; 109(5):363-368. PubMed ID: 30338680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robuvit® and endurance in triathlon: improvements in training performance, recovery and oxidative stress.
    Vinciguerra MG; Belcaro G; Cacchio M
    Minerva Cardioangiol; 2015 Oct; 63(5):403-9. PubMed ID: 26488613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.